Peptides continue to attract attention because of their broad therapeutic potential and high biological specificity. More than 80 peptide drugs are already FDA-approved, and many more remain in clinical development across areas such as metabolic disease, infectious disease, cancer, and orthopaedics. Their ability to interact with specific cellular pathways has made them especially promising in targeted medicine.

Still, therapeutic promise does not automatically translate into clinical usefulness. One of the clearest findings of this project was that peptide development is shaped just as much by limitation as by potential. Instability, rapid degradation, poor bioavailability, and route-of-delivery challenges all affect whether a peptide can become a viable treatment. These are not minor technical details. In many cases, they are the very issues that determine whether a compound remains scientifically interesting or becomes practically useful in medicine.

Different delivery routes create different complications. Oral peptides must survive the gastrointestinal environment. Topical and transdermal peptides must cross biological barriers effectively. Parenteral peptides often face short half-lives in the body. Because of this, peptide development often depends not only on biological mechanism, but also on chemical modification, improved formulation, and advances in delivery systems.